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Abstract
The lungs of cystic fibrosis (CF) patients are chronically colonized by a polymicrobial biofilm
community, leading to difficult-to-treat infections. To combat these infections, CF patients
are commonly treated with a variety of antibiotics. Understanding the dynamics of polymi-
crobial community composition in response to antibiotic therapy is essential in the search for
novel therapies. Culture-dependent quantification of individual bacteria from defined multi-
species biofilms is frequently carried out by plating on selective media. However, the influ-
ence of the selective agents in these media on quantitative recovery before or after
antibiotic treatment is often unknown. In the present study we developed selective media for
six bacterial species that are frequently co-isolated from the CF lung, i.e. Pseudomonas aer-
uginosa, Staphylococcus aureus, Streptococcus anginosus, Achromobacter xylosoxidans,
Rothia mucilaginosa, and Gemella haemolysans. We show that certain supplementations to
selective media strongly influence quantitative recovery of (un)treated biofilms. Hence, the
developed media were optimized for selectivity and quantitative recovery before or after
treatment with antibiotics of four major classes, i.e. ceftazidime, ciprofloxacin, colistin, or
tobramycin. Finally, in a proof of concept experiment the novel selective media were applied
to determine the community composition of multispecies biofilms before and after treatment
with tobramycin.
Introduction
Chronic respiratory tract infections are the main cause of morbidity and mortality in cystic
fibrosis (CF) patients [1]. In the CF lung environment, a polymicrobial community is the
source of these continuing infections, which results in an inflammatory response and eventu-
ally leads to lung deterioration [2–5]. Treatment of chronic lung infections in CF patients is
particularly challenging as members of the bacterial community form biofilms [6] which are
highly resistant to antimicrobial therapy [7,8]. The presence of biofilm-related infections has a
significant impact on clinical health outcomes, more specifically on lung function [9].
Interspecies interactions in polymicrobial communities have been shown to influence vari-
ous phenotypic characteristics of individual bacteria, such as antimicrobial susceptibility and
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production of virulence factors [10]. Hence, the importance of studying the role of complex
bacterial communities in disease progression and antibiotic susceptibility is generally acknowl-
edged [10,11]. To further elucidate the role of interspecies interactions in antibiotic suscepti-
bility of defined polymicrobial communities, in vitro studies have provided valuable insights
[12–14]. To this end, quantification of bacteria in multispecies consortia before and after anti-
biotic treatment is performed using culture-dependent and -independent techniques. One of
the most commonly used culture-dependent quantification methods for biofilms is determina-
tion of CFU (colony forming unit) counts on selective media. Most bacteria in the CF lung are
culturable, making this an effective approach for quantification of CF-related biofilms [15,16].
While selective media are available for a broad range of microorganisms, many are focused
solely on isolation from clinical or environmental samples and not on quantitative recovery
[17–20]. Few studies have investigated how the quantitative recovery on selective media com-
pares to that on a general medium [21–23], although this is essential to obtain an accurate pic-
ture of the amounts of particular taxa in bacterial communities. Furthermore, the influence of
antibiotic treatment on the recovery on a selective medium, which is often supplemented with
various antimicrobial substances, has not yet been investigated. This is important, as prior
antibiotic exposure could increase susceptibility to the selective agent(s) in the medium, and
therefore affect quantitative recovery.
The present study aims at developing selective media for six bacterial species commonly
found together in the CF lung in order to allow accurate quantification of individual species in
complex biofilm communities, before and after antibiotic treatment. Furthermore, previously
described selective media were evaluated in the process as well. Our approach for the develop-
ment of a selective medium for each of the species of interest consists of three steps. First, the
selectivity for each species was assessed using planktonic cultures. Second, the quantitative
recovery of single-species biofilms was compared between different media. Third, the single-
species biofilms were treated with antibiotics of four different classes after which the recovery
was evaluated again. Based on results obtained in each step, media composition was optimized
to improve quantitative recovery on the selective medium. Finally, the developed media were
tested in various experiments, to confirm their applicability for quantification of bacteria from
planktonic cultures and from biofilms, before and after antibiotic treatment.
Materials and methods
Bacterial strains and culturing conditions
Six bacterial species (clinical strains and one type strain; listed in Table 1) that are frequently
co-isolated from CF patients were selected for the development of selective media: Pseudomo-
nas aeruginosa, Staphylococcus aureus, Streptococcus anginosus, Achromobacter xylosoxidans,
Rothia mucilaginosa, and Gemella haemolysans [24–27]. For each species, at least one strain
was included that was isolated from the respiratory tract or, when this was not readily available
in public repositories, a type strain was used.
For all strains, liquid cultures were grown in BHI (Brain Heart Infusion) broth (Lab M) at
37˚C with shaking at 250 rpm until stationary phase. For S. anginosus and G. haemolysans, cul-
tures were incubated in microaerophilic conditions (±5% O2, ±15% CO2).
When indicated, microaerophilic conditions (±5% O2, ±15% CO2) were obtained using the
CampyGen Compact system (Oxoid, Thermo Fisher Scientific). To create an anaerobic envi-
ronment (<1% O2), AnaeroGen Compact sachets (Oxoid, Thermo Fischer Scientific) or can-
dle jars with the Anaerocult A system (Merck Millipore) were used.
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General media
For each of the six bacterial species included, a general medium with a theoretical recovery of
100% was used: Luria Bertani (LB; Lab M) agar for P. aeruginosa and S. aureus, Brain Heart
Infusion (BHI; Lab M) agar for S. anginosus, Nutrient agar (Lab M) for A. xylosoxidans and R.
mucilaginosa, and Columbia agar (CA; Lab M) or Columbia Blood Agar (CBA; Columbia
Agar base, Lab M + 5% defibrinated sheep blood, Biotrading) for G. haemolysans.
Media and chemicals used for development of the selective media
Previously described selective media. Previously described selective media were exam-
ined for selectivity and adjusted when necessary. For all media, each selective component was
examined to distinguish which components were essential for selective inhibition. For P. aeru-
ginosa, Pseudomonas Isolation Agar (PIA; BD Diagnostics) is described which uses 25 μg/mL
triclosan (Irgasan, Sigma Aldrich) as a selective agent since most bacterial species are suscepti-
ble while P. aeruginosa is resistant [30,31]. For S. aureus, Mannitol Salt Agar is widely used for
selection, based on a 7.5% NaCl concentration [32,33]. For S. anginosus, several media were
considered: NAS (nalidixic acid sulfamethazine) agar [19], Mitis Salivarius Agar (Sigma-
Aldrich) and Edwards medium (Oxoid, Thermo Fisher Scientific). For A. xylosoxidans,
MCXVAA medium is described [18], based on MacConkey agar supplemented with 5 mg/mL
xylose, 20 μg/mL vancomycin, 20 μg/mL aztreonam and 5 μg/mL amphotericin. For R. mucila-
ginosa, Rothia Mucilaginosa Selective Medium (RMSM) was previously developed, containing
50 μg/mL sodium selenite and 10 μg/mL colistin [22]. Finally, for G. haemolysans, a supple-
mented Edwards medium with 5 μg/mL colistin sulphate and 2.5 μg/mL oxolinic acid was
described [20].
Antimicrobial susceptibility testing. To identify potential selective or discriminating
antibiotic agents, an antibiotic susceptibility screening was performed. Susceptibility of the six
species to 25 antibiotics was assessed using the disk diffusion assay (S1 Table). To this end,
antibiotic disks were placed on inoculated BHI agar, according to the manufacturer’s instruc-
tions. Subsequently, the MIC90 of selected antibiotics (S2 Table) was determined using the
broth microdilution method according to EUCAST guidelines [34]. For all antibiotics, a range
of 0.5 – 256 μg/mL was tested in BHI or nutrient broth, depending on the general medium for
the intended strain.
Table 1. Overview of strains used in this study and isolation sites.
Species Strain Isolation site
Pseudomonas aeruginosa AA2 Lung; early CF infection [28]
AA44 Lung; late CF infection [28]
PAO1 Wound
Staphylococcus aureus SP123 Sputum of extubated patient [29]
Mu50 Wound
Streptococcus anginosus LMG 14696 Human throat
LMG 14502 Human respiratory tract
Achromobacter xylosoxidans LMG 26680 Human blood
LMG 14980 Sputum—Belgian CF patient
Rothia mucilaginosa DSM 20746 Bronchial secretion
ATCC 49042 Throat
Gemella haemolysans LMG 18984 Unknown
LMG 1068 Type strain
https://doi.org/10.1371/journal.pone.0187540.t001
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Selectivity testing
The ability of the medium to select for each of the six species was checked by plating. A plank-
tonic culture of each species, grown to stationary phase in BHI medium, was brought to an
OD 590 nm corresponding to approximately 5 x 107 CFU/mL, serially diluted and then plated
on the respective general medium as a positive control (theoretical recovery of 100%) and in
parallel on each of the candidate selective media (detection limit = 102 CFU/mL). The medium
was considered selective if distinct, countable colonies (clear growth) could be observed for
the intended species only. All media were incubated at 37˚C for 16 hours or until colonies
were of sufficient size for counting.
Formation of single- and multispecies biofilms
All biofilms were grown in a PVC flat-bottomed 96-well microtiter plate (Thermo Fisher) as
described previously, with modifications [35,36]. Stationary phase liquid cultures were diluted
in BHI supplemented with 2.5% lysed horse blood (horse blood from Biotrading, protocol for
lysed horse blood according to EUCAST). For single-species biofilms, 100 μL of a 2.5 x 107
CFU/mL suspension was transferred to a 96-well plate. For multispecies biofilms, 2.5 x 106
CFU of each strain were added per well to obtain an equal number of cells per species per well.
The inoculated 96-well plates were incubated at 37˚C for 24 hours in a microaerophilic envi-
ronment, thereby mimicking the low oxygen conditions in the CF lung [37,38].
Antibiotic treatment of biofilms
After 24 h, biofilms were treated with antibiotics as described previously [35]. Briefly, the bio-
films were rinsed with physiological saline solution (0.9% NaCl in milliQ water). Afterwards,
100 μL of medium (BHI + 2.5% lysed horse blood) was added to the control biofilms or 100 μL
of antibiotic solution in the same medium was added to the biofilms. Four antimicrobials from
four major antibiotic classes were selected. An overview of the antibiotics and their concentra-
tions used is shown in Table 2. As a starting point, one set of antibiotic concentrations that
gave a decrease of one to two logs of P. aeruginosa biofilm was used on all strains. Other con-
centrations of antibiotics were tested when no effect was observed for the other bacterial spe-
cies or in case of complete biofilm killing (detection limit of 102 CFU/mL) with the initial test
Table 2. Overview of antibiotic concentrations used for quantitative recovery experiments.
Ceftazidime Ciprofloxacin Colistin Tobramycin
Pseudomonas aeruginosa 2000 μg/mL 0.5 μg/mL 500 μg/mL 100 μg/mL
Staphylococcus aureus 2000 μg/mL 0.5 μg/mL 500 μg/mL 100 μg/mL
200 μg/mL 400 μg/mL
Streptococcus anginosus 2000 μg/mL 0.5 μg/mL 500 μg/mL 100 μg/mL
4 μg/mL
Achromobacter xylosoxidans 2000 μg/mL 0.5 μg/mL 500 μg/mL 100 μg/mL
1000 μg/mL 4 μg/mL
Rothia mucilaginosa 2000 μg/mL 0.5 μg/mL 500 μg/mL 100 μg/mL
1000 μg/mL 4 μg/mL
Gemella haemolysans 2000 μg/mL 0.5 μg/mL 500 μg/mL 100 μg/mL
4 μg/mL 25 μg/mL
Concentrations in italic show additional concentrations tested when either no effect or complete removal of biofilm growth occurred with the initial
concentrations.
https://doi.org/10.1371/journal.pone.0187540.t002
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concentration. All biofilms were incubated at 37˚C under microaerophilic conditions for an
additional 24 hours.
Biofilm quantification and recovery testing
Following antibiotic treatment of single or multispecies biofilms, biofilms were rinsed with
physiological saline. To quantify the number of colony forming units, biofilms were homoge-
nized by two rounds of vortexing (900 rpm, 5 min) and sonication (5 min; Branson Ultrasonic
bath), as described previously [35]. The resulting suspensions were serially diluted and plated
on the appropriate general and/or selective media. Plates were incubated at 37˚C overnight (16
hours) or until colonies were of sufficient size for counting. Recovery was considered quantita-
tive when no significant difference was observed between the number of CFU on the general
medium compared to the selective medium.
Statistics
All experiments were carried out at least in biological triplicate. Biofilm experiments contained
three technical replicates. Statistical analyses were performed in SPSS 23.0. Normality of the
data was checked through the Shapiro-Wilk test. Differences between the means of normally
distributed data were assessed by ANOVA-testing, followed by a Dunnett’s post hoc analysis,
or by an independent samples t-test. When normality was not confirmed, a Kruskal-Wallis
non-parametric test or Mann-Whitney test was performed. Means and standard deviations are
shown in each graph. Statistical significance is assumed when p-values are< 0.05.
Results & discussion
Assessment of selectivity and quantitative recovery of selective media
The results of the selectivity testing using planktonic cultures on previously described and
modified selective media are summarized in Fig 1. Following a positive outcome for selectivity,
the selective media were evaluated for quantitative recovery of cells from untreated biofilms
(Fig 2).
P. aeruginosa. We confirmed selectivity of Pseudomonas Isolation Agar (PIA, containing
25 μg/mL triclosan). In order to reduce the concentration of the selective agent, lower triclosan
concentrations (5 – 0.31 μg/mL in LB agar) were tested. All tested concentrations of triclosan
inhibited growth of all the other bacteria while allowing growth of P. aeruginosa after aerobic
overnight (16h) incubation. At concentrations of 1.25 μg/mL triclosan or higher, S. anginosus
showed growth of small colonies after 16h incubation which did not interfere with quantifica-
tion of P. aeruginosa. It is important to notice that longer incubation times (24-48h) lead to
interference of S. anginosus and A. xylosoxidans growth for quantification of P. aeruginosa,
highlighting the importance of selecting appropriate incubation times. Subsequently, recovery
of a single-species biofilm was tested on triclosan-supplemented LB agar. Addition of 5 μg/mL
triclosan resulted in a significant decrease of P. aeruginosa recovery (p< 0.05), while addition
of 2.5 and 1.25 μg/mL triclosan did not affect recovery. Hence, LB agar with 1.25 μg/mL triclo-
san (LB tricl 1.25) was used for further experiments.
S. aureus. Mannitol Salt Agar contains 7.5% NaCl, and we evaluated LB agar supple-
mented with the same amount of NaCl (LB NaCl). Aerobic overnight incubation showed that
only S. aureus was able to grow on this medium, confirming its selectivity. Furthermore, recov-
ery of biofilm cells on LB NaCl showed no difference in CFU counts compared to LB agar.
S. anginosus. NAS agar and Mitis Salivarius Agar combined with anaerobic incubation
were examined for selectivity but both media also supported growth of S. aureus and R.
Selective media for quantification of multispecies biofilms
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mucilaginosa in these conditions. Since 1.25 μg/mL triclosan permitted growth of S. anginosus,
LB supplemented with 1.25, 0.625 and 0.31 μg/mL triclosan was tested. Incubation took place
under anaerobic conditions to inhibit P. aeruginosa growth, as P. aeruginosa cannot grow
anaerobically without an alternative terminal electron acceptor [39,40]. This approach allowed
growth of S. anginosus only. In addition, LB with triclosan (LB 1.25, 0.625, 0.31) also allowed
Fig 1. Overview of selectivity experiments. The first column shows the intended species and an abbreviated name of the
medium, the second column (O2) shows aerobic (A) or anaerobic (AN) incubation, and the third column (t) shows incubation
times. Strains belonging to the same species showed the same results. Pa: P. aeruginosa AA2, PAO1, and AA44; Sa: S.
aureus SP123 and Mu50; Sag: S. anginosus LMG 14696 and LMG 14502; Ax: A. xylosoxidans LMG 26680 and LMG
14980; Rm: R. mucilaginosa DSM 20746 and ATCC 49042; Gh: G. haemolysans LMG 18984 and LMG 1068. Results are
shown for all tested media: Pseudomonas Isolation Agar (PIA), LB + triclosan (LB tricl), LB + 7.5% NaCl (LB NaCl),
nalidixic acid sulphamethazine agar (NAS), Mitis-salivarius agar (MSA), McConkey + 5 mg/mL xylose + 20 μg/mL
vancomycin (McXV), McConkey + 5 mg/mL xylose + 20 μg/mL vancomycin (McXV) + 20 μg/mL aztreonam (McXVA),
McConkey + aztreonam (McA), Rothia mucilaginosa selective medium (RMSM), nutrient agar + 5 μg/mL mupirocin + 10 μg/
mL colistin sulphate (NMC), Edwards medium + 10 μg/mL colistin sulphate (Edwards + col), Columbia blood agar + 32/
6.4 μg/mL co-trimoxazole (CBA + co32), Columbia agar + 32/6.4 μg/mL co-trimoxazole (CA + co32).
https://doi.org/10.1371/journal.pone.0187540.g001
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quantitative recovery of cells from single-species S. anginosus biofilms. Based on these results,
LB tricl 0.31 (with anaerobic incubation) was selected for further experiments.
A. xylosoxidans. MCXVAA (based on MacConkey agar supplemented with 5 μg/mL
xylose, 20 μg/mL vancomycin, 20 μg/mL aztreonam and 5 μg/mL amphotericin) [18], was con-
firmed to be a selective medium for A. xylosoxidans. The selective value of each of these com-
ponents (except for the anti-fungal amphotericin) was subsequently tested. MacConkey agar
inhibited growth of the Gram-positive bacteria, while addition of 20 μg/mL aztreonam inhib-
ited growth of P. aeruginosa. MacConkey agar with 1 μg/ml (or less) aztreonam also supported
growth of P. aeruginosa, while at concentrations of 10 μg/mL or higher, partial growth inhibi-
tion of A. xylosoxidans was observed. MacConkey supplemented with 5 μg/mL aztreonam
(McA5) was tested further and this medium allowed quantitative recovery of cells from
untreated A. xylosoxidans single-species biofilms.
R. mucilaginosa. RMSM only inhibited growth of P. aeruginosa, while the other five spe-
cies, including R. mucilaginosa, showed at least partial growth on this medium. Growth inhibi-
tion of P. aeruginosa was due to 10 μg/mL colistin sulphate, while sodium selenite did not
inhibit growth of any of the species investigated. Results from disk diffusion assays suggested
that mupirocin could be a suitable selective agent (S1 Table). Based on MIC values (S2 Table),
5 μg/mL mupirocin was added to nutrient agar, together with 10 μg/mL colistin sulphate. This
medium (NMC) consisting of nutrient agar, mupirocin and colistin sulphate, was selective for
R. mucilaginosa and allowed quantitative recovery of R. mucilaginosa from untreated biofilms.
G. haemolysans. We could not confirm selectivity for the previously described supple-
mented Edwards medium [20] as it did not allow growth of G. haemolysans in our experi-
ments. To develop a new selective medium for G. haemolysans, co-trimoxazole was used as
this antibiotic did not inhibit G. haemolysans growth in the disk diffusion assay, while inhibi-
tion zones were observed for all other species (S1 Table). Based on MIC values (S2 Table) for
all strains, 32/6.4 μg/mL co-trimoxazole was added to CBA. However, besides G. haemolysans,
S. aureus also showed growth on CBA agar with co-trimoxazole. Yet, in the absence of blood
complete growth inhibition was observed for all bacteria except for G. haemolysans, which lead
to the use of Columbia agar with 32/6.4 μg/mL co-trimoxazole (CA + co32) for further testing.
Our data showed that the CA + co32 medium allowed quantitative recovery of G. haemolysans
from untreated biofilms.
Quantitative recovery of biofilm cells after antibiotic treatment
Treated biofilms were plated on the developed selective media and on general media to assess
quantitative recovery following antibiotic treatment. Results are summarised in Fig 3. The
optimized selective media are presented in Table 3.
For P. aeruginosa, no significant difference was observed between the recovery of biofilm
cells on LB, LB with 1.25 μg/mL triclosan, or PIA after treatment with ceftazidime, ciprofloxa-
cin, colistin or tobramycin. Thus, LB tricl 1.25 with aerobic overnight incubation was an
appropriate medium for quantitative recovery of P. aeruginosa biofilm cells after antibiotic
treatment.
Fig 2. Quantification of untreated biofilms of the six bacterial species on candidate selective media compared to a general medium. (A) P.
aeruginosa AA2 (B) S. aureus SP 123 (C) S. anginosus LMG 14696 (D) A. xylosoxidans LMG 26680 (E) R. mucilaginosa DSM 20476 (F) G. haemolysans
LMG 18984. PIA = Pseudomonas Isolation Agar; LB tricl = LB agar supplemented with triclosan in various concentrations (μg/mL); LB NaCl = LB
supplemented with 7.5% NaCl; McA5 = McConkey agar supplemented with 5 μg/mL aztreonam; NMC = nutrient agar supplemented with 5 μg/mL
mupirocin and 10 μg/mL colistin sulphate; CA + co32 = Columbia agar with 32/6.4 μg/mL co-trimoxazole. Graphs show mean recovery and standard
deviations. * p < 0.05, n 3.
https://doi.org/10.1371/journal.pone.0187540.g002
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Similarly, in terms of recovery of S. aureus biofilms cells, there was no significant difference
between LB and LB + 7.5% NaCl after treatment with ceftazidime, ciprofloxacin, colistin or
tobramycin.
After treatment with ceftazidime, ciprofloxacin, colistin, or tobramycin, complete recovery
of S. anginosus biofilm cells was observed on LB supplemented with 1.25 μg/mL, 0.625 μg/mL
or 0.31 μg/mL triclosan (incubated anaerobically) as no differences with recovery on BHI were
observed. For further experiments LB with 0.31 μg/ml triclosan (LB tricl 0.31) was used
together with anaerobic incubation.
On McConkey agar with 5 μg/mL aztreonam, no significant difference in A. xylosoxidans
recovery was observed after treatment with ciprofloxacin, colistin or tobramycin, compared to
nutrient agar. However, after treatment with 2000 μg/mL ceftazidime, a significant decrease
(p< 0.05) in recovery on McA5 was noted compared to nutrient agar. Hence, a lower concen-
tration of aztreonam in MacConkey agar (1 μg/mL; McA1) was tested but this did not restore
recovery of the A. xylosoxidans biofilm treated with ceftazidime. To test whether this effect was
dependent on the concentration of the antibiotic, the concentration of ceftazidime was low-
ered to 1000 μg/mL, which did improve biofilm recovery on both tested media (McA1 and
McA5). However, as seen in the previous selectivity experiments, McA1 showed suboptimal
inhibition of P. aeruginosa and furthermore did not lead to increased recovery compared to
McA5. Taken together, McA5 was used as a selective medium for A. xylosoxidans. However, it
remains important to keep in mind that recovery on McA5 is affected when biofilms are
treated with ceftazidime, which varies dependent on the ceftazidime concentration. It is there-
fore important to consider that highly concentrated supplementations to selective media may
strongly influence quantitative recovery, in particular after preceding antibiotic treatment.
For R. mucilaginosa, no significant difference between the recovery on NMC and nutrient
agar was observed after treatment with either ceftazidime, ciprofloxacin, colistin or
Fig 3. Quantification of biofilms after antibiotic treatment on selective media compared to a general medium. (A) P. aeruginosa AA2 (B)
S. aureus SP 123 (C) S. anginosus LMG 14696 (D) A. xylosoxidans LMG 26680 (E) R. mucilaginosa DSM 20476 (F) G. haemolysans LMG 18984.
PIA = Pseudomonas Isolation Agar; LB tricl = LB agar supplemented with triclosan in various concentrations (μg/mL); LB NaCl = LB supplemented with
7.5% NaCl; McA5 = McConkey agar supplemented with 5 μg/mL aztreonam; NMC = nutrient agar supplemented with 5 μg/mL mupirocin and 10 μg/mL
colistin sulphate; CA + co32 = Columbia agar with 32/6.4 μg/mL co-trimoxazole. Graphs show mean recovery and standard deviations. * p < 0.05, n 3.
https://doi.org/10.1371/journal.pone.0187540.g003
Table 3. Composition of optimized selective media.
Selective medium Composition
Pseudomonas aeruginosa LB tricl 1.25 LB agar
1.25 μg/mL triclosan
Staphylococcus aureus LB NaCl LB agar
7.5% NaCl
Streptococcus anginosus LB tricl 0.31 (anaerobic) LB agar
0.31 μg/mL triclosan
Achromobacter xylosoxidans McA5 McConkey agar
5 μg/mL aztreonam
Rothia mucilaginosa NMC Nutrient agar
5 μg/mL mupirocin
10 μg/mL colistin sulphate
Gemella haemolysans CA + co32 Columbia agar
32/6.4 μg/mL co-trimoxazole
https://doi.org/10.1371/journal.pone.0187540.t003
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tobramycin. The NMC medium was used for quantitative recovery of R. mucilaginosa follow-
ing antibiotic treatment in further experiments.
After treatment with ceftazidime, ciprofloxacin, colistin or tobramycin, no significant dif-
ference in recovery of G. haemolysans on the developed selective medium (CA + co32) com-
pared to Columbia agar was observed, confirming the developed selective medium for
quantification after antibiotic treatment.
Validation of the selective media
For further validation of the six novel selective media, an additional strain (another clinical iso-
late or type strain) of each species was tested (S1 and S2 Figs). The developed selective media
allowed quantitative recovery of all the additional strains, with the exception of A. xylosoxidans
LMG 14980 after ceftazidime treatment, and G. haemolysans LMG 1068 for both the untreated
and treated (with ceftazidime and ciprofloxacin) single-species biofilm. Furthermore, a mixed
planktonic culture with a defined composition of the six bacteria (± 5 x 107 CFU/mL of each)
was plated on the six selective media and recovery was compared to the recovery of single-spe-
cies cultures. The results show no significant decrease in recovery of the strains in the mixed
culture compared to the single-species cultures showing that no growth inhibition occurred
and that the mixed culture did not decrease recovery of the individual strains (S3 Fig).
Proof of concept: Multispecies biofilms
Finally, as a proof of concept experiment to show that the media can be used to isolate strains
grown in a biofilm, the six bacterial species were quantified in multispecies biofilms, before
and after treatment with 100 μg/mL tobramycin. Biofilms were grown for 24h and subse-
quently treated for 24h in microaerophilic conditions (Fig 4). The results indicate that in the
multispecies biofilm P. aeruginosa, S. anginosus and G. haemolysans become less abundant
after treatment with tobramycin (p< 0.05), while S. aureus, A. xylosoxidans and R.
Fig 4. Proof of concept: Quantification of multispecies biofilms. A multispecies biofilm of the six bacterial
species was grown for 24 hours and subsequently incubated with fresh medium as an untreated control or
treated with 100 μg/mL tobramycin in medium for an additional 24 hours in microaerophilic conditions. Graphs
show mean recovery and standard deviations. The detection limit of 102 CFU/mL is represented by a dashed
line. * p < 0.05, n 3.
https://doi.org/10.1371/journal.pone.0187540.g004
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mucilaginosa are not affected by the treatment. Furthermore, biofilms were also grown for 48h
and subsequently treated for 24h (S4 Fig). All species, except for G. haemolysans, could be iso-
lated from this multispecies biofilm before and after treatment as well. These findings show
that community composition can be altered by antibiotic treatment. Hence, deciphering the
dynamics of multispecies consortia in response to antibiotic treatment using in vitro tools may
help improve our understanding of how multispecies communities respond to antibiotics in
vivo.
Conclusion
In this study, novel selective media were developed that allow quantitative recovery of (un)
treated multispecies biofilms comprised of six bacteria frequently co-isolated from CF samples.
We observed that incubation conditions, including incubation time and oxygen concentration,
were essential to enable selective recovery. Furthermore, evaluation of the developed selective
media for quantitative recovery of biofilms before and after antibiotic treatment revealed that
certain selective agents profoundly affect recovery. These findings highlight the importance of
keeping antibiotic supplementation in selective media to a minimum and to evaluate and
potentially modify available selective media to ensure optimal recovery. In conclusion, six
selective media were optimized for multispecies biofilm recovery, and we demonstrated that if
a selective medium is to be used for quantitative recovery of untreated or antibiotic-treated
cultures, prior recovery assessment is indispensable to avoid introducing biases for data
interpretation.
Supporting information
S1 Table. Antibiotic disk diffusion assay. Mean inhibition zones and standard deviations
(SD) are shown in mm per strain, ‘z’ shows that a clearer zone could be observed, yet no com-
plete inhibition occurred. This assay was performed for P. aeruginosa PAO1, AA2, and AA44;
S. aureus SP123; S. anginosus LMG 14696; A. xylosoxidans LMG 26680; R. mucilaginosa DSM
20746; G. haemolysans LMG 18984.
(PDF)
S2 Table. MIC data overview. Minimal Inhibitory Concentrations (range of 256–0.5 μg/mL)
were determined for gentamicin and mupirocin in nutrient broth, and for co-trimoxazole
(SMT-TMP) in BHI broth. -, not determined.
(PDF)
S1 Fig. Quantification of untreated (left) and treated (right) biofilms of additional strains.
(A) P. aeruginosa PAO1 and AA44, (B) S. aureus Mu50, PIA = Pseudomonas Isolation Agar;
LB tricl = LB agar supplemented with triclosan in various concentrations (μg/mL); LB
NaCl = LB supplemented with 7.5% NaCl. Graphs show mean recovery and standard devia-
tions.  p< 0.05, n 3.
(TIF)
S2 Fig. Quantification of untreated (left) and treated (right) biofilms of additional strains.
(C) S. anginosus LMG 14502, (D) A. xylosoxidans LMG 26680, (E) R. mucilaginosa ATCC
49042, and (F) G. haemolysans LMG 18984. LB tricl = LB agar supplemented with triclosan in
various concentrations (μg/mL); McA5 = McConkey agar supplemented with 5 μg/mL aztreo-
nam; NMC = nutrient agar supplemented with 5 μg/mL mupirocin and 10 μg/mL colistin sul-
phate; CA + co32 = Columbia agar with 32/6.4 μg/mL co-trimoxazole. Graphs show mean
recovery and standard deviations.  p< 0.05, n 3.
(TIF)
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S3 Fig. Validation of the novel selective media. Planktonic mono-species cultures and a
mixed culture were plated on the newly developed selective media and showed equal recovery.
Graphs show mean recovery and standard deviations.
(TIF)
S4 Fig. Proof of concept: Quantification of multispecies biofilms. A multispecies biofilm of
the six bacterial species was grown for 48 hours and subsequently incubated with fresh
medium as an untreated control or treated with 100 μg/mL tobramycin in medium for an
additional 24 hours in microaerophilic conditions. Graphs show mean recovery and standard
deviations. The detection limit of 102 CFU/mL is represented by a dashed line.  p< 0.05,
n 3.
(TIF)
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